| Full Name | Bhavi Patel |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 11 Years |
| Location | 1 Cooper Plz, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376951731 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 25MA10275500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morristown Medical Center | Morristown, NJ | Hospital |
| Overlook Medical Center | Summit, NJ | Hospital |
| Newton Medical Center | Newton, NJ | Hospital |
| Hackettstown Medical Center | Hackettstown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Practice Associates Medical Group | 5890703177 | 1116 |
News Archive
The Senate Finance Committee has begun discussing potential funding offsets for a compromise on mental health parity legislation passed by the House and Senate earlier in the 110th Congress, CongressDaily reports.
Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
› Verified 9 days ago
| Entity Name | Cmc Department Of Medicine Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679605554 PECOS PAC ID: 2163335878 Enrollment ID: O20050203000280 |
News Archive
The Senate Finance Committee has begun discussing potential funding offsets for a compromise on mental health parity legislation passed by the House and Senate earlier in the 110th Congress, CongressDaily reports.
Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
› Verified 9 days ago
| Entity Name | Cmc Department Of Medicine Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265565667 PECOS PAC ID: 2163335878 Enrollment ID: O20050504000294 |
News Archive
The Senate Finance Committee has begun discussing potential funding offsets for a compromise on mental health parity legislation passed by the House and Senate earlier in the 110th Congress, CongressDaily reports.
Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
› Verified 9 days ago
| Entity Name | Practice Associates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427016385 PECOS PAC ID: 5890703177 Enrollment ID: O20060330000690 |
News Archive
The Senate Finance Committee has begun discussing potential funding offsets for a compromise on mental health parity legislation passed by the House and Senate earlier in the 110th Congress, CongressDaily reports.
Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
› Verified 9 days ago
| Entity Name | Critical Care Physicians Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154682680 PECOS PAC ID: 5698931699 Enrollment ID: O20120719000039 |
News Archive
The Senate Finance Committee has begun discussing potential funding offsets for a compromise on mental health parity legislation passed by the House and Senate earlier in the 110th Congress, CongressDaily reports.
Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bhavi Patel, MD 1 Federal St # 200, Camden, NJ 08103-1088 Ph: (856) 356-4924 | Bhavi Patel, MD 1 Cooper Plz, Camden, NJ 08103-1461 Ph: (856) 342-2000 |
News Archive
The Senate Finance Committee has begun discussing potential funding offsets for a compromise on mental health parity legislation passed by the House and Senate earlier in the 110th Congress, CongressDaily reports.
Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus standard of care achieved undetectable levels of virus at week eight in an ongoing Phase II study, compared to 38% of patients receiving placebo plus SOC.
Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex, Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine.
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
› Verified 9 days ago
Howard Isadore Kesselheim, D.O. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2 Cooper Plz, Camden, NJ 08103 Phone: 855-632-2667 | |
Richard Arthur Hellander, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 817 Federal St, Camden, NJ 08103 Phone: 856-583-2400 | |
Sivakoti Nagireddy Guda, M.D Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Haddon Ave Fl 6, Camden, NJ 08103 Phone: 856-757-3500 | |
Steven Mudroch Ii, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 3 Cooper Plz Rm 513, Camden, NJ 08103 Phone: 856-963-3715 Fax: 856-635-1052 | |
Dr. Bradley Foster Bender, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-3150 | |
Dr. Amanda A Valvano, DO Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Niku Thomas, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2488 |